Transactions
8
Insider / Medline Inc.
Laabs Amanda H.
Chief Product Officer at Medline Inc.
- Company
- Medline Inc.
- Ticker
- MDLN
- First filing on record
- March 6, 2026
- Latest trade on record
- June 15, 2026
- SEC filings
- EDGAR ↗
Laabs Amanda H., Chief Product Officer at Medline Inc., has disclosed 8 transactions in MDLN since March 6, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $69K at the reported prices. The latest was filed June 17, 2026, 2 days after the trade; 6 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
1
Avg. disclosure lag
60.4d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Laabs Amanda H. made no purchases and 1 sale worth $69K, plus 7 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Laabs Amanda H. has traded 1 stock on record; the largest by dollars is MDLN.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 7 | 2,313,255 | — |
| F | Shares withheld for tax | 1 | 1,889 | $69K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 1 · $69K |
| 2025 | 6 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MDLN | Sell F | June 15, 2026 | June 17, 2026 | 2d | 1,889 | $37 | $69K | Form 4 ↗ | ||
| MDLN | Other A | December 16, 2025 | March 6, 2026 | 80d | 220,813 | — | — | lateindirectderivative | Form 4 ↗ | |
| MDLN | Other A | December 16, 2025 | March 6, 2026 | 80d | 132,771 | — | — | lateindirectderivative | Form 4 ↗ | |
| MDLN | Other A | December 16, 2025 | March 6, 2026 | 80d | 189,352 | — | — | lateindirectderivative | Form 4 ↗ | |
| MDLN | Other A | December 16, 2025 | March 6, 2026 | 80d | 1,242,391 | — | — | lateindirectderivative | Form 4 ↗ | |
| MDLN | Other A | December 16, 2025 | March 6, 2026 | 80d | 251,070 | — | — | lateindirectderivative | Form 4 ↗ | |
| MDLN | Other A | March 5, 2026 | March 6, 2026 | 1d | 25,788 | — | — | Form 4 ↗ | ||
| MDLN | Other A | December 16, 2025 | March 6, 2026 | 80d | 251,070 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 17, 2026 | Form 4 | 0001193125-26-274310 | 1 | published | EDGAR ↗ |
| March 6, 2026 | Form 4 | 0001193125-26-096666 | 7 | published | EDGAR ↗ |
Other insiders at Medline Inc.
- Hellman & Friedman Capital Partners X (Parallel), L.P. Insider 34 rows
- BCP 8 Holdings Mozart Manager L.L.C. Insider 28 rows
- BX Mozart ML-1 Holdco L.P. Insider 18 rows
- Carlyle Group Inc. Insider 18 rows
- Carlyle Mozart Coinvestment Holdings, L.P. Insider 18 rows
- GIC Private Ltd Insider 16 rows
- Golwas Douglas P Chief Commercial Officer 14 rows
- Boyle James M Chief Executive Officer 13 rows
- Abrams William J See Remarks 10 rows
- BX Mozart ML-2 Holdco L.P. Insider 10 rows
Everyone on file, with contracts and lobbying under the company's name: Medline Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 8 | March 6, 2026 | June 17, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.